BNGO
Bionano Genomics, Inc.
Next earnings Aug 12, 2026 · consensus $-0.70 EPS, $7.63M rev
Last earnings -0.8% on 2026-05-13
$1.14
▲ +1.79%$1.14▼ -65.14%
over 1Y
L $1.09EODHDH $4.92
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.8%
1W-0.9%
1M-7.3%
3M-1.7%
YTD-28.3%
1Y-65.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.66x); but revenue declined -7.4% YoY.
Revenue (FY2025) $28.5M · FY2025
Bionano Genomics, Inc. shows $28.5M in FY2025 revenue (-7.4% YoY), a -92.6% net margin, and -59.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $18.0M | $27.8M | $36.1M | $30.8M | $28.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$77.1M | -$132M | -$215M | -$104M | -$33.3M |
| Net income | -$72.4M | -$133M | -$232M | -$112M | -$26.4M |
| Diluted EPS | -$0.26 | -$4.58 | -$408.60 | -$88.13 | -$4.85 |
| Net margin | -402.8% | -476.9% | -643.7% | -364.0% | -92.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$9.65M
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-208.7%
FCF yield-129.3%
Quality & risk
ROIC (est.)-59.3%
Free cash flow-$16.3M
Total debt$0.00
Net cash$2.99M
Altman Z-Score-14.17 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+268.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Other event2026-06-24
- 8-K Officer / director change2026-06-05
- 8-K Other event2026-05-28
- 8-K Shareholder vote2026-05-14
- 8-K Earnings results2026-05-13
- 10-Q Quarterly report2026-05-13
- S-3 Shelf registration (potential raise)2026-05-08
- 8-K Officer / director change2026-05-06
- DEF 14A Proxy statement2026-04-02
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-242026-06-24open ↗8-KPeriod ending 2026-06-022026-06-05open ↗4Period ending 2026-06-032026-06-03open ↗4Period ending 2026-06-032026-06-03open ↗4Period ending 2026-06-032026-06-03open ↗4Period ending 2026-06-032026-06-03open ↗8-KPeriod ending 2026-05-282026-05-28open ↗4Period ending 2026-05-142026-05-14open ↗4Period ending 2026-05-142026-05-14open ↗4Period ending 2026-05-142026-05-14open ↗4Period ending 2026-05-142026-05-14open ↗4Period ending 2026-05-142026-05-14open ↗
Frequently asked
- Is Bionano Genomics, Inc. (BNGO) a buy?
- BNGO currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.66x); but revenue declined -7.4% YoY.
- What is Bionano Genomics, Inc.'s quality score?
- BNGO scores 57.82352941176471/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001411690, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 11:36:49 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.